Previous 10 | Next 10 |
home / stock / evotf / evotf news
JUST - EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV HAMBURG, GERMANY / ACCESSWIRE / February 7, 2024 ...
2024-01-22 15:43:08 ET Evotec SE (EVO) Business Update Conference Call January 22, 2024, 09:00 AM ET Company Participants Volker Braun - SVP, Head of Global IR & ESG Iris Löw-Friedrich - Chairwoman Mario Polywka - Interim CEO Conference Call Partic...
HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec's...
EVOTEC JOINS FORCES WITH THE CROHN'S & COLITIS FOUNDATION'S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE ("IBD") THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR T...
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH HAMBURG, GERMANY / ACCESSWIRE / January 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced...
PARTNERSHIP COMBINES OWKIN'S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN'S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYM...
HAMBURG, GERMANY / ACCESSWIRE / January 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to...
EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY ("GHDC") AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC'S IPSC-DERIVED HIGH-T...
GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PA...
EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ("NMPA") AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC'S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD ("JINGXIN") WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA HAMBURG, GE...
News, Short Squeeze, Breakout and More Instantly...
Evotec Ag Ord Company Name:
EVOTF Stock Symbol:
OTCMKTS Market:
HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024. The Company is going to hold a conference call to discuss the resul...
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY BERLIN A...
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D&...